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Conclusions   
Background   Results  
Successful knockdown of ILK protein expression 
in all five lines was confirmed via Western blot.  
ILK inhibition led to significantly decreased 
secretion of chemokines RANTES, IP-10, in 
KTC1, and MIP1-alpha in the papillary thyroid 
cancer cell lines KTC1 and TPC1. This 
established a new role for ILK in regulating the 
thyroid cancer microenvironment. Decreased 
secretion of chemokines in ILK knock down cell 
lines seems to be specific for papillary thyroid 
cancers. No significant changes were seen in 
anaplastic or follicular thyroid cancers. 
Further research is needed to determine 
mechanisms by which ILK alters chemokine 
secretion and how this effects the types of 
immune cells that infiltrate the tumor 
microenvironment.  
 
 ILK inhibition led to significantly decreased 
secretion of RANTES in the cell lines KTC1 
(1261 vs 6.8 pg/mL, P<0.01) and TPC1 (462.87 
vs 5.58 pg/mL, P <0.01).  
 
Material and Methods  
CC chemokine levels in ILK knockdown 
thyroid panel; decreased RANTES secretion, 
high secretion MCP-1 in PTC 
A panel of 5 human thyroid cancer cell lines 
(papillary cancer lines KTC1, TPC1, BCPAP; 
follicular cancer line FTC133; anaplastic cancer 
line hTh112) were transfected with either ILK or 
control siRNA, in triplicate. Cytokine 65-Plex 
Discovery Assays (Eve Technologies) were used 
to assess chemokine secretion. Western blots 
were completed on the 5 cell lines to evaluate 
ILK protein knock down in triplicate.  
IP-10 in KTC1 (3773.06 vs 12.86 pg/mL, 
P<0.01) and TPC1 (2459.66 vs 2.71 pg/mL, 
P<0.01). 
CXC Chemokine levels in ILK knockdown 
thyroid panel; decreased IP-10 in PTC  
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MIP1-alpha (KTC1, 223.69 vs 20.7 pg/mL, 
P<0.01; TPC1, 94.48 vs 22.33 pg/mL, P=0.01).   
CC chemokine levels in ILK knockdown 
thyroid panel; decreased MIP-1a secretion in 
PTC 
Over the past three decades, the incidence of 
thyroid cancer in the United States has been 
dramatically increasing. For patients with 
aggressive and undifferentiated forms, 
treatment options are limited and prognosis is 
poor. Predictors of death from thyroid cancer 
include the presence of gross local invasion 
and the development of distant metastases. It 
has been shown that the tumor 
microenvironment facilitates local invasion and 
metastasis through the recruitment of the 
immune system.  
 Although a variety of immune cells are 
recruited during carcinogenesis, including 
macrophages, natural killer cells, and 
lymphocytes, tumors are able to preferentially 
recruit sub-types that promote cancer growth, 
including tumor-associated macrophages and 
regulatory T cells. Small signaling molecules 
called chemokines, such as RANTES, IP-10, 
MCP-1, and MIP1-alpha, both attract pro-
malignant immune cells as work to enhance the 
aggressiveness of cancer cells themselves.  
Our laboratory has previously shown a critical 
role of the protein integrin-linked kinase (ILK) in 
the aggressiveness of thyroid cancers, via 
promoting anchorage-independent growth, 
EMT, inhibition of apoptosis, and increased cell 
migration and invasion. 
ILK Cellular Signaling 
Preliminary data showed that ILK was 
expressed in both the tumor tissue and 
surrounding stroma, however its expression in 
the stroma was more intense. Further 
evaluation of these samples showed that the 
increase in stromal ILK expression correlated 
with the presence of positive lymph nodes and 
also correlated with a shorter duration of 
recurrence-free survival (P=0.005).  
 
We thus investigated the role of ILK in 
secretion of chemokines from thyroid tumor as 
a possible mechanism for modulating the tumor 
stroma.  
Increase in stromal ILK expression 
correlates with lymph node metastasis and 
shorter recurrence-free survival 
Successful knock down of ILK expression in 
thyroid cancer cell line panel 
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